Overcoming MHC-I downregulation by targeting METTL3, or similar RNA-modifying enzymes, may potentiate other T-cell-based cancer therapies, including CAR-T and adoptive T-cell transfer, and it might also be useful for stimulating T-cell responses in chronic viral infections. The gene discussed is METTL3; the disease is cancer.